New Therapies for Acute Myeloid Leukemia

New Orleans, LA US
December 18, 2019

Acute myeloid leukemia (AML) is a type of cancer in which the bone marrow produces abnormal myeloblasts, red blood cells, or platelets. AML was incurable 50 years ago, however, with advanced therapeutic options, it can be treated with favorable outcomes in 35-40% of the patients who are 60 years of age or younger. AML is the most common leukemia in adults, with an incidence of 3 to 8 cases per 100,000 adults per year. The median survival rate after 5 years in younger patients, those aged 18-60 years, is approximately 40%. The rate of survival decreases to 10% in patients above 60 years of age. Until recently, patients have typically been treated with similar chemotherapeutic regimens, however, the treatment options for AML have expanded due to discovery of genetic abnormalities. This presentation will review the background for AML, typical presentation, including objective and subjective findings, diagnosis, and prognosis of AML. The presentation will review the new therapies available for AML and review the literature supporting these therapies. 

Target Audience

  • Pharmacists
  • Pharmacy technicians

Learning Objectives

Pharmacist learning objectives

  1. Describe the clinical presentation and diagnosis of patients with acute myeloid leukemia
  2. Discuss the new targeted therapies for AML
  3. Utilize pharmacy literature to support the use and place in therapy for pharmacotherapy options for the treatment of AML

Pharmacy technician learning objectives

  1. Define acute leukemia
  2. Identify the brand and generic names of pharmacological treatments for AML
  3. Identify the safety precautions necessary for handling the pharmacologic agents used to treat AML
Course summary
Available credit: 
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CEU – Attendance
Course opens: 
Course expires: 
Event starts: 
12/18/2019 - 1:30pm
Event ends: 
12/18/2019 - 2:30pm
Ochsner Medical Center
1514 Jefferson Highway
New Orleans, LA 70121
United States
Relevant financial relationships: Planning committee members and the presenter have nothing to disclose
Planning committee members
Jessica Foy, PharmD, BCPS, BCOP
Ochsner Medical Center
Breanne Peyton-Thomas, PharmD, BCOP
Ochsner Medical Center
Course reviewer
James Lichauer, Pharm.D., BCPS, FASHP
PI Program Director, Pharmacy
Dhara Naik, PharmD
PGY-1 Pharmacy Resident
Ochsner Medical Center
In support of improving patient care, this activity has been planned and implemented by Vizient, Inc. and Ochsner Medical Center.  Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation Statements:
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.
Universal Activity Number: JA0006103-9999-19-246-L04-P
Universal Activity Number: JA0006103-9999-19-246-L04-T
Vizient, Inc. will award CEUs to each participant who successfully completes this program. The CEU is a nationally recognized unit of measure for continuing education and training programs that meet certain criteria (1 contact hour = 0.1 CEU).

Available Credit

  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CEU – Attendance


Please login or register to take this course.